江蘇威奇達藥業有限公司簡介
江蘇威奇達藥業有限公司（原名上海現代制藥海門有限公司）為中國醫藥集團旗下化學制藥工業平臺上海現代制藥股份有限公司（股票代碼600420）的下屬公司，于2010年2月在江蘇省南通市成立，注冊資本8億元人民幣。公司定位為高端、特色原料藥研發生產基地，主要產品涵蓋抗感染類、內分泌類、心腦血管類、抗腫瘤類、抗抑郁類、大健康類等領域，遠銷國際市場，涵蓋20多個國家和地區。公司致力于成為專業、服務、創新、可靠的制藥服務平臺。通過多年的沉淀，擁有完備的生產技術能力、完善的質量管理、EHS管理體系，為全球客戶提供從中試放大到商業化生產的核心服務和各種認證注冊申報支持。公司已先后通過NMPA、FDA、WHO等權威認證，為全球知名藥企長期提供服務。
公司設有研發/技術中心，依托中國醫藥集團旗下中國醫藥工業研究總院，擁有強大的研發技術、專業的人才團隊和先進的設備儀器。已通過國家知識產權管理認證，且為“江蘇省高新技術企業”，先后被認定為 “江蘇省高端原料藥合成工程技術研究中心”、“江蘇省企業技術中心”、“江蘇省醫藥行業誠信企業”。阿奇霉素、L-α-甘油磷酰膽堿、鹽酸奈必洛爾產品獲得高新技術產品認證。依托公司技術隊伍和質量體系，我們有能力和經驗，開展高技術含量、高附加值、低排放的CMO&CDMO服務。
公司主要產品包括：
阿奇霉素、L-α-甘油磷酰膽堿、鹽酸奈必洛爾、硫酸阿巴卡韋、硫酸阿扎那韋、紫檀芪、白藜蘆醇、氧化白藜蘆醇、硫辛酸、甲基門冬氨酸 咖啡酸苯乙酯、二香草基四氫呋喃、釓布醇。
Jiangsu Weiqida Pharmaceutical Co., Ltd. (formerly known as Shanghai Shyndec Pharmaceutical Haimen Co., Ltd.) is the third subsidiary of Shanghai Shyndec Pharmaceutical Co., Ltd. (stock code: 600420), a chemical and pharmaceutical industry platform under China National Pharmaceutical Group Co., Ltd. (Sinopharm). It is the wholly-owned subsidiary of Sinopharm Weiqida Pharmaceutical Co., Ltd. Jiangsu Weiqida was established in Nantong City, Jiangsu Province in February 2010 with a registered capital of 800 million yuan. The company is positioned as an exclusive high-end and characteristic API R&D and production base. Its main products cover antiviral, anti-infective, cardiovascular and cerebrovascular, and general health fields, and are exported to the international market, covering more than 20 countries and regions. It has a high market share. The company is committed to become a professional, service, innovative and reliable pharmaceutical service platform. “All for health, Health for all”. Through years of precipitation, we have complete production technology capabilities, perfect quality management, and EHS management systems, providing core services from pilot scale-up to commercial production and various certification, registration support to global customers. We have successively passed NMPA, FDA, WHO and other authoritative certifications, and have provided long-term services for world-renowned pharmaceutical companies.
Jiangsu Weiqida has a R&D/technology center, relying on the China State Institute of Pharmaceutical Industry under the China National Pharmaceutical Group, with strong R&D technology, professional talent team and advanced equipment. It has passed the national intellectual property management certification, and is certificated as “Jiangsu High-tech Enterprise”. It has been successively recognized as “Jiangsu High-end API Synthesis Engineering Technology Research Center”, “Jiangsu Enterprise Technology Center”, and “Jiangsu Pharmaceutical Industry Integrity Enterprise”. Azithromycin, L-α-Glycerophosphoryl Choline, and Nebivolol Hydrochloride were certified as high-tech products. In the future, the company will actively promote R&D innovation, focusing on the development of high-tech, high value-added, low-emission featured products, and building the company into a CDMO customized processing industry base.